Amino Innovations Launches Wholesale Program to Bring Human Peptide Science to Clinics, Retailers., and Wellness Centers Nationwide

Vancouver, British Columbia – December 2, 2025 – Pangea Wellness Inc. (CSE: PNGA) (OTC: PNGAF) ("**Pangea**" or the "**Company**"), is pleased to announce that its subsidiary, Amino Innovations Inc. ("Amino Innovations"), has officially launched its U.S. wholesale and B2B distribution program, expanding access to its growing line of non-injectable, peptide-based wellness products.

This new program introduces a comprehensive distribution model that brings advanced peptide formulations into professional environments that have traditionally relied on injectable therapies. Many clinics, wellness centers, and performance facilities are familiar with peptides administered through traditional injection protocols. Amino Innovations is now providing a more accessible alternative through premium oral capsules, topical creams, hair serums, and its upcoming flagship Peptide Patch product line.

Additionally, the program allows participating clinics and retailers to promote Amino Innovations products through on-site educational materials and mock packaging. All fulfilment, e-commerce logistics, customer support, and compliance requirements are managed directly by Amino Innovations through its integrated online platform and United States distribution network.

"Our mission is to make human peptide science accessible and simple for practitioners and consumers," said Damon Michaels, President and Co-Founder of Amino Innovations. "We oversee all operational and compliance functions to ensure a seamless experience for our partners, which allows them to focus on supporting their clients while introducing a new potential revenue stream and a higher level of customer experience."

The wholesale program is suited to a wide range of professional and retail environments seeking to integrate science-backed, non-injectable peptide products. Ideal partners include integrative and functional medicine clinics, regenerative and longevity centers, IV therapy and wellness lounges, sports medicine and recovery facilities, med spas, dermatology and aesthetic clinics, biohacking and fitness studios, and pharmacy or apothecary style boutiques. These settings are well positioned to feature Amino Innovations product, which complement traditional peptide programs while offering broader accessibility for everyday use.

All Amino Innovations peptide-based formulations are manufactured in cGMP certified facilities in the United States. Products are third party tested and formulated exclusively with human endogenous peptides including BPC-157, GHK Cu, Epitalon, Pinealon, Thymosin Alpha 1, and Thymosin Beta 4.

Clinics and retailers interested in joining the Amino Innovations wholesale network can learn more or apply at AminoInnovations.com/wholesale.

About Pangea Wellness Inc.

Pangea Wellness Inc. is a North American manufacturer specializing in clean-label foods and innovative wellness products. Through its subsidiary Amino Innovations, the Company offers advanced, non-injectable peptide delivery systems that support recovery, cognitive function, and overall health.

On Behalf of the Board of Directors

"Pratap Sandhu"

Pratap Sandhu
CEO, Corporate Secretary and Director

+1 (604) 765-8069
media@pangea-wellness.com

Forward-Looking Information

This news release contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Forward-looking statements in this news release include statements related to Amino Innovation's wholesale distribution program and the anticipated benefits from the wholesale distribution program. The forward–looking statements and information are based on certain key expectations and assumptions made by the management of the Company. As a result, there can be no assurance that the acquisition or related matters will be completed as proposed or at all. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward–looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward–looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the ability of the Company to complete its planned future activities and anticipated business plans. Other factors may also adversely affect the future results or performance of the Company, including general economic, market or business conditions, changes in the financial markets and changes in laws, regulations and policies affecting the Company's operations and the Company's limited operating history. Accordingly, readers should not place undue reliance on the forward–looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward– looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward–looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.